ID

30123

Description

A Multicenter Study of rhFGF 18 in Patients With Knee Osteoarthritis Not Requiring Surgery; ODM derived from: https://clinicaltrials.gov/show/NCT01033994

Lien

https://clinicaltrials.gov/show/NCT01033994

Mots-clés

Versions (1)
  1. 14/05/2018 14/05/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

14 mai 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Knee Osteoarthritis NCT01033994

Anglais

Eligibility Knee Osteoarthritis NCT01033994

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. male or female >= 40 years of age; females must be postmenopausal or surgically sterile
Description

Age | Postmenopausal state | Female Sterilization

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0232970
UMLS CUI [3]
C0015787
2. established diagnosis of primary femoro-tibial oa of the target knee by standard american college of rheumatology criteria for at least six months (clinical and radiological criteria)
Description

Osteoarthritis femorotibial Target Knee | Disease length

Type de données

boolean

Alias
UMLS CUI [1,1]
C0029408
UMLS CUI [1,2]
C1269072
UMLS CUI [1,3]
C1521840
UMLS CUI [1,4]
C0022742
UMLS CUI [2]
C0872146
3. radiological disease stage 2 or 3 (i.e., clear evidence of oa, but not most advanced disease) in the target knee according to the kellgren-lawrence grading of knee oa
Description

Disease Radiologic | Osteoarthritis Target Knee Kellgren-Lawrence score

Type de données

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0205483
UMLS CUI [2,1]
C0029408
UMLS CUI [2,2]
C1521840
UMLS CUI [2,3]
C0022742
UMLS CUI [2,4]
C3177117
4. no major knee surgery (e.g., partial or total knee replacement, interventional arthroscopy) in the target knee planned for at least 12 months after first injection of the study drug
Description

Absence Major surgery Target Knee | Absence Partial Knee Replacement | Absence Total Knee Replacement | Absence Arthroscopy Interventional

Type de données

boolean

Alias
UMLS CUI [1,1]
C0332197
UMLS CUI [1,2]
C0679637
UMLS CUI [1,3]
C1521840
UMLS CUI [1,4]
C0022742
UMLS CUI [2,1]
C0332197
UMLS CUI [2,2]
C0864243
UMLS CUI [3,1]
C0332197
UMLS CUI [3,2]
C0086511
UMLS CUI [4,1]
C0332197
UMLS CUI [4,2]
C0003904
UMLS CUI [4,3]
C0184661
5. documented need for symptomatic prn (as needed)-treatment for oa in the target knee with systemic non-steroidal anti-inflammatory drugs (nsaids) and/or other analgesics.
Description

Therapeutic procedure PRN Symptomatic | Osteoarthritis Target Knee | NSAIDs Systemic | Analgesics Systemic

Type de données

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0558288
UMLS CUI [1,3]
C0231220
UMLS CUI [2,1]
C0029408
UMLS CUI [2,2]
C1521840
UMLS CUI [2,3]
C0022742
UMLS CUI [3,1]
C0003211
UMLS CUI [3,2]
C0205373
UMLS CUI [4,1]
C0002771
UMLS CUI [4,2]
C0205373
6. total womac score between 24 and 72 (out of 96, corresponding to mild, moderate, or severe, but not extreme oa symptoms) for the target knee while on oral symptomatic treatment at baseline
Description

Target Knee WOMAC scale | Therapeutic procedure Symptomatic Oral

Type de données

boolean

Alias
UMLS CUI [1,1]
C1521840
UMLS CUI [1,2]
C0022742
UMLS CUI [1,3]
C3472647
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C0231220
UMLS CUI [2,3]
C1527415
7. full understanding of the requirements of the study and willingness to comply with all study visits and assessments
Description

Protocol Compliance

Type de données

boolean

Alias
UMLS CUI [1]
C0525058
8. patients must have read and understood the informed consent form, and must have signed it prior to any study-related procedure
Description

Informed Consent

Type de données

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
any condition, including laboratory findings and findings in the medical history or in the pre-study assessments, that in the opinion of the investigator constitutes a risk or contraindication for participation in the study or that could interfere with the study objectives, conduct or evaluation
Description

Condition At risk Study Subject Participation Status | Laboratory finding At risk Study Subject Participation Status | Medical History At risk Study Subject Participation Status | Assessment Pre-study At risk Study Subject Participation Status | Medical contraindication Study Subject Participation Status | Condition Interferes with Study Protocol | Condition Interferes with Completion of clinical trial | Condition Interferes with Evaluation

Type de données

boolean

Alias
UMLS CUI [1,1]
C0348080
UMLS CUI [1,2]
C1444641
UMLS CUI [1,3]
C2348568
UMLS CUI [2,1]
C0587081
UMLS CUI [2,2]
C1444641
UMLS CUI [2,3]
C2348568
UMLS CUI [3,1]
C0262926
UMLS CUI [3,2]
C1444641
UMLS CUI [3,3]
C2348568
UMLS CUI [4,1]
C1516048
UMLS CUI [4,2]
C1527048
UMLS CUI [4,3]
C1444641
UMLS CUI [4,4]
C2348568
UMLS CUI [5,1]
C1301624
UMLS CUI [5,2]
C2348568
UMLS CUI [6,1]
C0348080
UMLS CUI [6,2]
C0521102
UMLS CUI [6,3]
C2348563
UMLS CUI [7,1]
C0348080
UMLS CUI [7,2]
C0521102
UMLS CUI [7,3]
C2732579
UMLS CUI [8,1]
C0348080
UMLS CUI [8,2]
C0521102
UMLS CUI [8,3]
C1261322
clinically significant abnormal hematology (hemoglobin, leucocytes, and platelets), or blood chemistry values (aspartate aminotransferase (ast), alanine aminotransferase (alt), alkaline phosphatase (alp), bilirubin, and creatinine
Description

Hematology abnormal | Hemoglobin measurement | White Blood Cell Count procedure | Platelet Count measurement | Blood chemistry abnormal | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Alkaline phosphatase measurement | Serum total bilirubin measurement | Creatinine measurement, serum

Type de données

boolean

Alias
UMLS CUI [1]
C0475182
UMLS CUI [2]
C0518015
UMLS CUI [3]
C0023508
UMLS CUI [4]
C0032181
UMLS CUI [5]
C0438258
UMLS CUI [6]
C0201899
UMLS CUI [7]
C0201836
UMLS CUI [8]
C0201850
UMLS CUI [9]
C1278039
UMLS CUI [10]
C0201976
receipt of any investigational product or any experimental therapeutic procedure within the last 12 weeks preceding screening
Description

Investigational New Drugs | Therapies, Investigational

Type de données

boolean

Alias
UMLS CUI [1]
C0013230
UMLS CUI [2]
C0949266
participation in fih study 27575 or in a different cohort of this study
Description

Study Subject Participation Status | First in Human Clinical Trial

Type de données

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2,1]
C3641799
UMLS CUI [2,2]
C0008976
i.a. treatment of the target knee with steroids or hyaluronic acid derivatives within the 3 months before baseline
Description

Therapeutic procedure Target Knee | Steroids | Hyaluronic Acid Derivative

Type de données

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C1521840
UMLS CUI [1,3]
C0022742
UMLS CUI [2]
C0038317
UMLS CUI [3,1]
C0020196
UMLS CUI [3,2]
C1527240
for mad cohorts, any contra-indications to mri according to mri guidelines
Description

Medical contraindication MRI

Type de données

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C0024485
any condition that would interfere with efficacy or safety assessments in the target knee
Description

Condition Interferes with Evaluation | Condition Interferes with Safety Assessment | Relationship Target Knee

Type de données

boolean

Alias
UMLS CUI [1,1]
C0348080
UMLS CUI [1,2]
C0521102
UMLS CUI [1,3]
C0220825
UMLS CUI [2,1]
C0348080
UMLS CUI [2,2]
C0521102
UMLS CUI [2,3]
C0549076
UMLS CUI [3,1]
C0439849
UMLS CUI [3,2]
C1521840
UMLS CUI [3,3]
C0022742
any drug or food supplement with potential disease-modifying effect (glucosamine, diacerin, chondroitin sulfate) unless given at a stable dose over at least 4 weeks prior to first injection
Description

Pharmaceutical Preparations Changing Disease | Dietary Supplements Changing Disease | Glucosamine | diacetylrhein | Chondroitin Sulfates

Type de données

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0392747
UMLS CUI [1,3]
C0012634
UMLS CUI [2,1]
C0242295
UMLS CUI [2,2]
C0392747
UMLS CUI [2,3]
C0012634
UMLS CUI [3]
C0017718
UMLS CUI [4]
C0057678
UMLS CUI [5]
C0008466
use of electrotherapy or acupuncture for oa, unless there is a stable regimen for at least 4 weeks before baseline
Description

Electric Stimulation Therapy Degenerative polyarthritis | Acupuncture Degenerative polyarthritis

Type de données

boolean

Alias
UMLS CUI [1,1]
C0013787
UMLS CUI [1,2]
C0029408
UMLS CUI [2,1]
C0394664
UMLS CUI [2,2]
C0029408
any known active infections, including suspicion of intra-articular infection and/or infections that may compromise the immune system such as hiv, hepatitis b or hepatitis c infection
Description

Communicable Diseases | Suspicion Communicable Disease Intra-articular | Communicable Diseases Impairing Immune system | HIV Infection | Hepatitis B | Hepatitis C

Type de données

boolean

Alias
UMLS CUI [1]
C0009450
UMLS CUI [2,1]
C0242114
UMLS CUI [2,2]
C0009450
UMLS CUI [2,3]
C0442108
UMLS CUI [3,1]
C0009450
UMLS CUI [3,2]
C0221099
UMLS CUI [3,3]
C0020962
UMLS CUI [4]
C0019693
UMLS CUI [5]
C0019163
UMLS CUI [6]
C0019196
history of sarcoma and/or of other active malignancy within five years, except adequately treated basal cell or squamous cell carcinoma of the skin
Description

Sarcoma | Malignant Neoplasms | Exception Basal cell carcinoma Treated | Exception Squamous cell carcinoma of skin Treated

Type de données

boolean

Alias
UMLS CUI [1]
C1261473
UMLS CUI [2]
C0006826
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0007117
UMLS CUI [3,3]
C1522326
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0553723
UMLS CUI [4,3]
C1522326
signs and symptoms suggestive of transmissible spongiform encephalopathy
Description

Signs and Symptoms Suggestive of Prion Disease

Type de données

boolean

Alias
UMLS CUI [1,1]
C0037088
UMLS CUI [1,2]
C0332299
UMLS CUI [1,3]
C0162534
secondary osteoarthritis: e.g., joint dysplasias, aseptic osteonecrosis, acromegaly, paget's disease, ehlers-danlos syndrome, gaucher's disease, stickler's syndrome, joint infection, hemophilia, hemochromatosis, calcium pyrophosphate deposition disease, or neuropathic arthropathy whatever the cause
Description

Secondary osteoarthritis | Joint dysplasia | Osteonecrosis aseptic | Acromegaly | Paget's Disease | Ehlers-Danlos Syndrome | Gaucher Disease | Stickler syndrome | Arthropathy associated with infection | Hemophilia | Hemochromatosis | Calcium pyrophosphate deposition disease | Neurogenic arthropathy

Type de données

boolean

Alias
UMLS CUI [1]
C2732281
UMLS CUI [2]
C1395954
UMLS CUI [3]
C0391980
UMLS CUI [4]
C0001206
UMLS CUI [5]
C1368019
UMLS CUI [6]
C0013720
UMLS CUI [7]
C0017205
UMLS CUI [8]
C0265253
UMLS CUI [9]
C0157749
UMLS CUI [10]
C0684275
UMLS CUI [11]
C0018995
UMLS CUI [12]
C0553730
UMLS CUI [13]
C0003892
Retour au début de la page

Similar models

Eligibility Knee Osteoarthritis NCT01033994

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Age | Postmenopausal state | Female Sterilization
Item
1. male or female >= 40 years of age; females must be postmenopausal or surgically sterile
boolean
C0001779 (UMLS CUI [1])
C0232970 (UMLS CUI [2])
C0015787 (UMLS CUI [3])
Osteoarthritis femorotibial Target Knee | Disease length
Item
2. established diagnosis of primary femoro-tibial oa of the target knee by standard american college of rheumatology criteria for at least six months (clinical and radiological criteria)
boolean
C0029408 (UMLS CUI [1,1])
C1269072 (UMLS CUI [1,2])
C1521840 (UMLS CUI [1,3])
C0022742 (UMLS CUI [1,4])
C0872146 (UMLS CUI [2])
Disease Radiologic | Osteoarthritis Target Knee Kellgren-Lawrence score
Item
3. radiological disease stage 2 or 3 (i.e., clear evidence of oa, but not most advanced disease) in the target knee according to the kellgren-lawrence grading of knee oa
boolean
C0012634 (UMLS CUI [1,1])
C0205483 (UMLS CUI [1,2])
C0029408 (UMLS CUI [2,1])
C1521840 (UMLS CUI [2,2])
C0022742 (UMLS CUI [2,3])
C3177117 (UMLS CUI [2,4])
Absence Major surgery Target Knee | Absence Partial Knee Replacement | Absence Total Knee Replacement | Absence Arthroscopy Interventional
Item
4. no major knee surgery (e.g., partial or total knee replacement, interventional arthroscopy) in the target knee planned for at least 12 months after first injection of the study drug
boolean
C0332197 (UMLS CUI [1,1])
C0679637 (UMLS CUI [1,2])
C1521840 (UMLS CUI [1,3])
C0022742 (UMLS CUI [1,4])
C0332197 (UMLS CUI [2,1])
C0864243 (UMLS CUI [2,2])
C0332197 (UMLS CUI [3,1])
C0086511 (UMLS CUI [3,2])
C0332197 (UMLS CUI [4,1])
C0003904 (UMLS CUI [4,2])
C0184661 (UMLS CUI [4,3])
Therapeutic procedure PRN Symptomatic | Osteoarthritis Target Knee | NSAIDs Systemic | Analgesics Systemic
Item
5. documented need for symptomatic prn (as needed)-treatment for oa in the target knee with systemic non-steroidal anti-inflammatory drugs (nsaids) and/or other analgesics.
boolean
C0087111 (UMLS CUI [1,1])
C0558288 (UMLS CUI [1,2])
C0231220 (UMLS CUI [1,3])
C0029408 (UMLS CUI [2,1])
C1521840 (UMLS CUI [2,2])
C0022742 (UMLS CUI [2,3])
C0003211 (UMLS CUI [3,1])
C0205373 (UMLS CUI [3,2])
C0002771 (UMLS CUI [4,1])
C0205373 (UMLS CUI [4,2])
Target Knee WOMAC scale | Therapeutic procedure Symptomatic Oral
Item
6. total womac score between 24 and 72 (out of 96, corresponding to mild, moderate, or severe, but not extreme oa symptoms) for the target knee while on oral symptomatic treatment at baseline
boolean
C1521840 (UMLS CUI [1,1])
C0022742 (UMLS CUI [1,2])
C3472647 (UMLS CUI [1,3])
C0087111 (UMLS CUI [2,1])
C0231220 (UMLS CUI [2,2])
C1527415 (UMLS CUI [2,3])
Protocol Compliance
Item
7. full understanding of the requirements of the study and willingness to comply with all study visits and assessments
boolean
C0525058 (UMLS CUI [1])
Informed Consent
Item
8. patients must have read and understood the informed consent form, and must have signed it prior to any study-related procedure
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Condition At risk Study Subject Participation Status | Laboratory finding At risk Study Subject Participation Status | Medical History At risk Study Subject Participation Status | Assessment Pre-study At risk Study Subject Participation Status | Medical contraindication Study Subject Participation Status | Condition Interferes with Study Protocol | Condition Interferes with Completion of clinical trial | Condition Interferes with Evaluation
Item
any condition, including laboratory findings and findings in the medical history or in the pre-study assessments, that in the opinion of the investigator constitutes a risk or contraindication for participation in the study or that could interfere with the study objectives, conduct or evaluation
boolean
C0348080 (UMLS CUI [1,1])
C1444641 (UMLS CUI [1,2])
C2348568 (UMLS CUI [1,3])
C0587081 (UMLS CUI [2,1])
C1444641 (UMLS CUI [2,2])
C2348568 (UMLS CUI [2,3])
C0262926 (UMLS CUI [3,1])
C1444641 (UMLS CUI [3,2])
C2348568 (UMLS CUI [3,3])
C1516048 (UMLS CUI [4,1])
C1527048 (UMLS CUI [4,2])
C1444641 (UMLS CUI [4,3])
C2348568 (UMLS CUI [4,4])
C1301624 (UMLS CUI [5,1])
C2348568 (UMLS CUI [5,2])
C0348080 (UMLS CUI [6,1])
C0521102 (UMLS CUI [6,2])
C2348563 (UMLS CUI [6,3])
C0348080 (UMLS CUI [7,1])
C0521102 (UMLS CUI [7,2])
C2732579 (UMLS CUI [7,3])
C0348080 (UMLS CUI [8,1])
C0521102 (UMLS CUI [8,2])
C1261322 (UMLS CUI [8,3])
Hematology abnormal | Hemoglobin measurement | White Blood Cell Count procedure | Platelet Count measurement | Blood chemistry abnormal | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Alkaline phosphatase measurement | Serum total bilirubin measurement | Creatinine measurement, serum
Item
clinically significant abnormal hematology (hemoglobin, leucocytes, and platelets), or blood chemistry values (aspartate aminotransferase (ast), alanine aminotransferase (alt), alkaline phosphatase (alp), bilirubin, and creatinine
boolean
C0475182 (UMLS CUI [1])
C0518015 (UMLS CUI [2])
C0023508 (UMLS CUI [3])
C0032181 (UMLS CUI [4])
C0438258 (UMLS CUI [5])
C0201899 (UMLS CUI [6])
C0201836 (UMLS CUI [7])
C0201850 (UMLS CUI [8])
C1278039 (UMLS CUI [9])
C0201976 (UMLS CUI [10])
Investigational New Drugs | Therapies, Investigational
Item
receipt of any investigational product or any experimental therapeutic procedure within the last 12 weeks preceding screening
boolean
C0013230 (UMLS CUI [1])
C0949266 (UMLS CUI [2])
Study Subject Participation Status | First in Human Clinical Trial
Item
participation in fih study 27575 or in a different cohort of this study
boolean
C2348568 (UMLS CUI [1])
C3641799 (UMLS CUI [2,1])
C0008976 (UMLS CUI [2,2])
Therapeutic procedure Target Knee | Steroids | Hyaluronic Acid Derivative
Item
i.a. treatment of the target knee with steroids or hyaluronic acid derivatives within the 3 months before baseline
boolean
C0087111 (UMLS CUI [1,1])
C1521840 (UMLS CUI [1,2])
C0022742 (UMLS CUI [1,3])
C0038317 (UMLS CUI [2])
C0020196 (UMLS CUI [3,1])
C1527240 (UMLS CUI [3,2])
Medical contraindication MRI
Item
for mad cohorts, any contra-indications to mri according to mri guidelines
boolean
C1301624 (UMLS CUI [1,1])
C0024485 (UMLS CUI [1,2])
Condition Interferes with Evaluation | Condition Interferes with Safety Assessment | Relationship Target Knee
Item
any condition that would interfere with efficacy or safety assessments in the target knee
boolean
C0348080 (UMLS CUI [1,1])
C0521102 (UMLS CUI [1,2])
C0220825 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C0549076 (UMLS CUI [2,3])
C0439849 (UMLS CUI [3,1])
C1521840 (UMLS CUI [3,2])
C0022742 (UMLS CUI [3,3])
Pharmaceutical Preparations Changing Disease | Dietary Supplements Changing Disease | Glucosamine | diacetylrhein | Chondroitin Sulfates
Item
any drug or food supplement with potential disease-modifying effect (glucosamine, diacerin, chondroitin sulfate) unless given at a stable dose over at least 4 weeks prior to first injection
boolean
C0013227 (UMLS CUI [1,1])
C0392747 (UMLS CUI [1,2])
C0012634 (UMLS CUI [1,3])
C0242295 (UMLS CUI [2,1])
C0392747 (UMLS CUI [2,2])
C0012634 (UMLS CUI [2,3])
C0017718 (UMLS CUI [3])
C0057678 (UMLS CUI [4])
C0008466 (UMLS CUI [5])
Electric Stimulation Therapy Degenerative polyarthritis | Acupuncture Degenerative polyarthritis
Item
use of electrotherapy or acupuncture for oa, unless there is a stable regimen for at least 4 weeks before baseline
boolean
C0013787 (UMLS CUI [1,1])
C0029408 (UMLS CUI [1,2])
C0394664 (UMLS CUI [2,1])
C0029408 (UMLS CUI [2,2])
Communicable Diseases | Suspicion Communicable Disease Intra-articular | Communicable Diseases Impairing Immune system | HIV Infection | Hepatitis B | Hepatitis C
Item
any known active infections, including suspicion of intra-articular infection and/or infections that may compromise the immune system such as hiv, hepatitis b or hepatitis c infection
boolean
C0009450 (UMLS CUI [1])
C0242114 (UMLS CUI [2,1])
C0009450 (UMLS CUI [2,2])
C0442108 (UMLS CUI [2,3])
C0009450 (UMLS CUI [3,1])
C0221099 (UMLS CUI [3,2])
C0020962 (UMLS CUI [3,3])
C0019693 (UMLS CUI [4])
C0019163 (UMLS CUI [5])
C0019196 (UMLS CUI [6])
Sarcoma | Malignant Neoplasms | Exception Basal cell carcinoma Treated | Exception Squamous cell carcinoma of skin Treated
Item
history of sarcoma and/or of other active malignancy within five years, except adequately treated basal cell or squamous cell carcinoma of the skin
boolean
C1261473 (UMLS CUI [1])
C0006826 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0007117 (UMLS CUI [3,2])
C1522326 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0553723 (UMLS CUI [4,2])
C1522326 (UMLS CUI [4,3])
Signs and Symptoms Suggestive of Prion Disease
Item
signs and symptoms suggestive of transmissible spongiform encephalopathy
boolean
C0037088 (UMLS CUI [1,1])
C0332299 (UMLS CUI [1,2])
C0162534 (UMLS CUI [1,3])
Secondary osteoarthritis | Joint dysplasia | Osteonecrosis aseptic | Acromegaly | Paget's Disease | Ehlers-Danlos Syndrome | Gaucher Disease | Stickler syndrome | Arthropathy associated with infection | Hemophilia | Hemochromatosis | Calcium pyrophosphate deposition disease | Neurogenic arthropathy
Item
secondary osteoarthritis: e.g., joint dysplasias, aseptic osteonecrosis, acromegaly, paget's disease, ehlers-danlos syndrome, gaucher's disease, stickler's syndrome, joint infection, hemophilia, hemochromatosis, calcium pyrophosphate deposition disease, or neuropathic arthropathy whatever the cause
boolean
C2732281 (UMLS CUI [1])
C1395954 (UMLS CUI [2])
C0391980 (UMLS CUI [3])
C0001206 (UMLS CUI [4])
C1368019 (UMLS CUI [5])
C0013720 (UMLS CUI [6])
C0017205 (UMLS CUI [7])
C0265253 (UMLS CUI [8])
C0157749 (UMLS CUI [9])
C0684275 (UMLS CUI [10])
C0018995 (UMLS CUI [11])
C0553730 (UMLS CUI [12])
C0003892 (UMLS CUI [13])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial